LONDON (Alliance News) - Biotechnology company Puretech Health PLC said on Wednesday subsidiary company Akili Interactive Labs Inc received USD11.9 million in financing from two bio-pharmaceutical companies.
In January, software-based treatment developer Akili said it had raised USD30.5 million from investors including JAZZ Venture Partners, Canepa Advanced Healthcare Fund and PureTech. This additional investment brings the total round of Series B financing to USD42.4 million.
With investments from Amgen Ventures and M Ventures, Akili now has four relationships with "major bio-pharmaceutical companies", including its existing partnership with Pfizer Inc and an investment from Shire Pharmaceuticals PLC. PureTech owns around 59% of Akili.
"The commitment from Amgen Ventures and M Ventures, alongside existing investors, demonstrates additional validation and confidence in Akili. We believe that these and other relationships signify our leadership position at the interface of mental health and digital medicine," said Daphe Zohar, PureTech co-founder and chief executive.
Shares in PureTech were flat at 149.06 pence Wednesday morning.
By Lucy Heming; lucyheming@alliancenews.com
Copyright 2016 Alliance News Limited. All Rights Reserved.
PureTech (PRTC)